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Antenatal 
corticosteroids to 
reduce preterm deaths 
in low-income settings
In their Comment1 on the use of 
antenatal corticosteroids to reduce 
preterm infant deaths, Kishwar Azad 
and Anthony Costello advise “extreme 
caution” before scale-up in low-income 
settings. They emphasise maternal 
sepsis as a concern but cite only one 
trial in which dexamethasone resulted 
in a significant increase in fever 
that required antibiotic treatment 
compared with controls (relative 
risk [RR] 2·05, 95% CI 1·14–3·69; 
118 women).1,2 We suggest that 
this ﬁ nding alone does not reﬂ ect a 
balanced assessment of the paucity of 
evidence available.2 
In a systematic review of antenatal 
corticosteroid treatment to accelerate 
fetal lung maturation, only four 
of 21 randomised controlled trials 
report on puerperal sepsis outcomes 
for dexamethasone versus no ante-
natal corticosteroids and these 
show moderate heterogeneity 
(I² 38%) (RR 1·74, 95% CI 1·04–2·89; 
536 women).2 Only two trials were 
in low-income to middle-income 
countries and had very diﬀ erent results: 
the Dexiprom trial from South Africa 
(0·57, 0·17–1·89; 204 women) and one 
trial from Jordon (4·19, 0·94–18·68; 
139 women). Incidence of maternal 
postnatal fever did not differ in 
two trials, the US Collaborative trial 
(0·93, 0·56–1·53; 682 women) and 
the Dexiprom trial in South Africa 
(1·00, CI 0·36–2·75; 204 women). Most 
reassuringly, no signiﬁ cant diﬀ erence 
was reported in the incidence of 
chorioamnionitis in four trials of 
dexamethasone (1·35, 0·89–2·05; 
575 women) or postnatal fever 
in two trials of dexamethasone 
(0·94, 0·60–1·47; 886 women).2 No 
trials of dexamethasone reported on 
maternal intrapartum fever when 
antibiotics were given. 
Trials of betamethasone versus 
dexamethasone in accelerating fetal 
lung maturation have not reported 
on maternal infectious outcomes.3 
We are currently undertaking a large-
scale trial to compare the efficacy 
of intramuscular dexamethasone 
versus betamethasone in reducing 
childhood neurosensory disability, 
with maternal infection as a 
secondary outcome.4 Currently, no 
published data suggest a major risk 
of maternal infection with the use 
of antenatal corticosteroids and 
none are available to allow conﬁ dent 
assertion that dexamethasone 
increases the risk. According to 
present recommendations, the major 
safety concern surrounding the use 
of antenatal corticosteroids is repeat 
doses.5
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